Published within
|«
«
|
...
|
116
|
117
|
118
|
119
|
120
|
121
|
122
|
123
|
124
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
Expert View
|
Pooled data released at the APA 2012 suggest that Forest's Viibryd combines a fast onset of antidepressant activity with a favorable side-effect profile, satisfying two important unmet needs in depression pharmacotherapy. Conversely, results from the Phase III program for levomilnacipran are less impressive, suggesting that the drug offers little benefit over other drugs in its class.
Published By Datamonitor
|
15 May 2012 |
|
Expert View
|
The DSM-5, the latest edition of the gold-standard diagnostic guidelines in psychiatry throughout the world, is due to be unveiled in May 2013. Given the huge size of the psychiatry drug market, any changes made to the diagnoses of conditions such as depression, bipolar disorders, and schizophrenia - however slight - will be of great interest to the pharmaceutical industry.
Published By Datamonitor
|
15 May 2012 |
|
Expert View
|
New clinical data were presented at APA 2012 that showed that Latuda is effective as an adjunctive treatment for bipolar depression and may possess a procognitive effect in schizophrenia patients. These findings set Latuda apart from the competition and may allow the drug to shine in a fiercely competitive antipsychotics market.
Published By Datamonitor
|
15 May 2012 |
|
CommentWire
|
Lundbeck has secured another success in its pipeline as Lu AE58054 met its primary cognition endpoint in a Phase II study in moderate Alzheimer's disease. The drug, a 5-HT6 receptor antagonist, looks set to rival GlaxoSmithKline's SB-742457 as a novel class of Alzheimer's disease drugs races to the reach the market.
Published By Datamonitor
|
29 May 2012 |
|
CommentWire
|
New positive data from a pivotal Phase III trial of Genzyme's Aubagio will serve to support its anticipated approval in the US and EU, demonstrating significant reduction in annualized relapse rate. Despite these positive results, the drug will still face fierce competition from marketed oral Gilenya and Biogen's pipeline oral candidate BG-12, given their far superior efficacy profiles.
Published By Datamonitor
|
06 Jun 2012 |
|
CommentWire
|
Genentech, a member of the Roche Group, has announced FDA approval of Perjeta in combination with Herceptin and docetaxel for the treatment of HER2-positive metastatic breast cancer. Perjeta's approval will enhance Roche's extensive portfolio of HER2-targeted therapies and help maintain sales revenue after Herceptin's patent expires.
Published By Datamonitor
|
13 Jun 2012 |
|
Expert View
|
New clinical trial data for canagliflozin have revealed that its blood glucose-lowering abilities show superiority to blockbuster gold-standard Januvia, with the added benefit of weight loss. The potential for first-to-market SGLT-2 inhibitor status in the US and its good safety and efficacy profile boost canagliflozin's chances for success in a crowded diabetes market.
Published By Datamonitor
|
14 Jun 2012 |
|
CommentWire
|
The FDA's ODAC has recommended Kyprolis, the multiple myeloma treatment from Proteolix and Onyx Pharmaceuticals, despite ongoing cardiac and hepatic toxicity concerns. If approved, the drug will threaten Velcade's share of the myeloma market and could pose a threat to Johnson & Johnson's future revenues.
Published By Datamonitor
|
21 Jun 2012 |
|
Expert View
|
Ablynx is looking for a new partner to progress the development of anti-tumor necrosis factor (TNF) pipeline drug ozoralizumab, which utilizes novel "nanobody" technology to achieve some differentiating factors in this profitable but crowded market. The new results are promising, but true differentiation among anti-TNF brands is hard to achieve.
Published By Datamonitor
|
27 Jun 2012 |
|
CommentWire
|
Eli Lilly's pipeline schizophrenia drug LY2140023 failed to separate from placebo in a large Phase II study, unlike the active comparator risperidone. Evidence is mounting against the drug's efficacy, although Lilly's commitment to a large development program will ensure that no hasty decisions are made regarding the drug's future.
Published By Datamonitor
|
12 Jul 2012 |
|
|«
«
|
...
|
116
|
117
|
118
|
119
|
120
|
121
|
122
|
123
|
124
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.